Immix Biopharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMX research report →
Companywww.immixbio.com
Immix Biopharma, Inc. , a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
- CEO
- Ilya Rachman
- IPO
- 2021
- Employees
- 18
- HQ
- Los Angeles, CA, US
Price Chart
Valuation
- Market Cap
- $486.44M
- P/E
- -9.78
- P/S
- 0.00
- P/B
- 4.06
- EV/EBITDA
- -11.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -73.23%
- ROIC
- -42.25%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-29,438,613 · -36.21%
- EPS
- $-0.89 · -17.11%
- Op Income
- $-27,211,131
- FCF YoY
- -56.37%
Performance & Tape
- 52W High
- $11.61
- 52W Low
- $1.87
- 50D MA
- $9.55
- 200D MA
- $5.64
- Beta
- 0.12
- Avg Volume
- 761.33K
Get TickerSpark's AI analysis on IMMX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 21, 25 | CHANG NANCY T | other | 39,643 |
| Dec 10, 25 | Rachman Ilya M | buy | 746 |
| Dec 8, 25 | Morris Gabriel S | other | 156,000 |
| Dec 10, 25 | Morris Gabriel S | buy | 770 |
| Dec 8, 25 | Morris Gabriel S | other | 60,000 |
| Sep 17, 25 | Rachman Ilya M | buy | 2,500 |
| Sep 16, 25 | Morris Gabriel S | buy | 2,600 |
| Sep 8, 25 | CHANG NANCY T | other | 0 |
| Sep 8, 25 | CHANG NANCY T | other | 0 |
| Sep 8, 25 | CHANG NANCY T | other | 316,455 |
Our IMMX Coverage
We haven't published any research on IMMX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMMX Report →